We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Thermo Fisher (TMO): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Thermo Fisher Scientific (TMO - Free Report) will report quarterly earnings of $5.20 per share in its upcoming release, pointing to a year-over-year increase of 1%. It is anticipated that revenues will amount to $10.83 billion, exhibiting an increase of 4.5% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues- Laboratory Products and Biopharma Services' will likely reach $5.75 billion. The estimate indicates a year-over-year change of +2%.
The average prediction of analysts places 'Revenues- Specialty Diagnostics' at $1.16 billion. The estimate indicates a year-over-year change of +1.2%.
According to the collective judgment of analysts, 'Revenues- Life Sciences Solutions' should come in at $2.52 billion. The estimate points to a change of +7.9% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Analytical Instruments' reaching $1.74 billion. The estimate indicates a year-over-year change of +1.3%.
Shares of Thermo Fisher have experienced a change of +11% in the past month compared to the +6.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TMO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q1 Potential of Thermo Fisher (TMO): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Thermo Fisher Scientific (TMO - Free Report) will report quarterly earnings of $5.20 per share in its upcoming release, pointing to a year-over-year increase of 1%. It is anticipated that revenues will amount to $10.83 billion, exhibiting an increase of 4.5% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues- Laboratory Products and Biopharma Services' will likely reach $5.75 billion. The estimate indicates a year-over-year change of +2%.
The average prediction of analysts places 'Revenues- Specialty Diagnostics' at $1.16 billion. The estimate indicates a year-over-year change of +1.2%.
According to the collective judgment of analysts, 'Revenues- Life Sciences Solutions' should come in at $2.52 billion. The estimate points to a change of +7.9% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Analytical Instruments' reaching $1.74 billion. The estimate indicates a year-over-year change of +1.3%.
View all Key Company Metrics for Thermo Fisher here>>>Shares of Thermo Fisher have experienced a change of +11% in the past month compared to the +6.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TMO is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .